Skip to main content
Log in

Comparison of bisoprolol and diazepam in the treatment of cardiac neurosis

  • Experimental Pharmacology
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Summary

In order to compare the beta blockers bisoprolol and diazepam in the treatment of cardiac neurosis, 40 patients (16 males and 24 females, mean age: 39 ± 11 years) were examined in a double-blind, crossover study. Following a 4-week placebo period, patients were randomized to receive either bisoprolol 10 mg daily or diazepam 5 mg twice daily for 4 weeks. After a second 4-week washout period on placebo, patients were switched to the alternative regimen for a further 4 weeks. At the end of the placebo periods and during each phase of treatment, the following parameters were evaluated: somatic symptoms by self-assessment questionnaire, anxiety state by Hamilton rating scale, reaction time to both aroustic and visual stimuli, blood pressure, and heart rate. Both treatments were effective in reducing somatic symptoms of cardiac neurosis, but bisoprolol was significantly more effective than diazepam (p < 0.01). On the contrary, diazepam was superior to bisoprolol in improving the Hamilton scale related to psychic symptoms. Only diazepam prolonged reaction times. Both treatments were well tolerated; however, 12 patients complained of drowsiness and nine of sedation under diazepam. In conclusion, bisoprolol appeared to be as effective as diazepam in the treatment of cardiac neurosis, but with better effects on somatic symptoms and without affecting patients' psychomotor performance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Da Costa JM. On irritable heart: A clinical study of a functional cardiac disorder and its consequences. Am J Med Sci 1871;61:2–8.

    Google Scholar 

  2. Homgren A, Johnson B, Levander L. Low physical working capacity in suspected heart cases due to inadequate adjustment on peripheral blood flow. Acta Med Scand 1957;159:413–421.

    Google Scholar 

  3. Gorlin R, Brachfeld N, Turner JD, et al. The idiopathic high cardiac output state. J Clin Invest 1959;38:2145–2157.

    Google Scholar 

  4. Gorlin R. The hyperkinetic heart syndrome. JAMA 1962;182:823–826.

    Google Scholar 

  5. Editorial. The hyperkinetic heart. Lancet 1982;2:967–968.

  6. Hartshorne H. On heart disease in the army. Am J Med Sci 1984;48:89–95.

    Google Scholar 

  7. Masini U. La nevrosi cardiaca, una sindrome mal definita. Proposta di una classificazione nosografica. Cardiologia 1985;30:67–71.

    Google Scholar 

  8. Breggin PR. The psychophysiology of anxiety. J Nerv Ment Dis 1964;139:558–568.

    Google Scholar 

  9. Mola B. Cardiac neurosis recognition and management. Cardiovasc Clin 1971;2:222–230.

    Google Scholar 

  10. Patron G, Duperier CL, Degeorges M. Le traitment de l'asthenie neuro-circulatoire. Rev Prat 1976;26:261–268.

    Google Scholar 

  11. Frohlic ED, Dustan HP, Page IH. Hyperdynamic betaadrenergic circulation state. Arch Intern Med 1969;123:1–7.

    Google Scholar 

  12. Frohlic ED, Tarazi RC, Dustan HF. Hyperdynamic betaadrenergic circulatory state increased beta-receptor responsiveness. Arch Intern Med 1969;123:1–7.

    Google Scholar 

  13. Bollinger A. Treatment of the hyperkinetic heart syndrome with propranolol. Cardiologia 1966;49 (Suppl 2):68–82.

    Google Scholar 

  14. Schweitzer P, Pivonka M, Gregorova J. The hemodynamic effects of beta-adrenergic blockade in patients with neurocirculatory asthemia. Cardiologia 1968;52:246–251.

    Google Scholar 

  15. Bourne HR, Thomson PD, Melmon K. Diagnosis and treatment of beta-adrenergic receptor hyperresponsiveness. A critical appraisal. Arch Intern Med 1970;125:1063–1066.

    Google Scholar 

  16. Marsden CW. Propranolol in neurocirculatory asthenia and anxiety. Postgrad Med 1971;47(Suppl):100–105.

    Google Scholar 

  17. Furberg CD. Beta-adrenergic receptor blocking drugs in hypertrophic cardiomiopathy, autonomically mediated cardiovascular functional disorders and Fallot's tetralogy. Drugs 1974;7:106–117.

    Google Scholar 

  18. Wolf E, Brown K, Stern S. Effects of beta-receptor blocking agents propranolol and practolol on ST changes in neurocirculatory asthenia. Br Heart J 1974;36:872–879.

    Google Scholar 

  19. Guazzi M, Polese A, Magrini F, et al. Long-term treatment of hyperkinetic heart syndrome with propranolol. Am J Med Sci 1975;270:465–474.

    Google Scholar 

  20. Rimon R, Kampman R, Viukari M. Propranolol in the treatment of neurocirculatory asthenia: An open pilot study. Isr J Psychiatry Relat Sci 1979;17:144–148.

    Google Scholar 

  21. Tyrer P. Use of beta-blocking drugs in psychiatry and neurology. Drugs 1980;20:300–308.

    Google Scholar 

  22. Noyes R. Beta-blocking drugs and anxiety. Psychosomatics 1982;23:155–170.

    Google Scholar 

  23. Michael JA. A placebo-controlled, double-blind trial of oxprenolol versus diazepam in the treatment of anxiety and stress. In: Kielholz P, ed. Psychosomatic cardiovascular disorders. Berne: Hans Huber, 1981:191–196.

    Google Scholar 

  24. Suzman MM. Use of beta-adrenergic receptor blocking agents in psychiatry. In: Neuropharmacology of central nervous system and behavioral disorders. London: Academic Press, 1981: 339–391.

    Google Scholar 

  25. Baathen LR, Gisholt K, Hellebo R, et al. Effect of alprenolol in patients with neurocirculatory asthenia: A controlled double-blind study in general practice. Pharmatherapeutica 1977;1:381–388.

    Google Scholar 

  26. Meibach RC, Mullane SF, Binstock G. A placebo-controlled multicenter trial of propranolol and chlordiazepoxide in the treatment of anxiety. Curr Ther Res 1987;41:1965–1976.

    Google Scholar 

  27. Lader MH, Tyrer PJ. Central and peripheral effects of propranolol and sotalol in normal human subjects. Br J Pharmacol 1972;45:557–560.

    Google Scholar 

  28. Knapp E, Raas E, Aigner A, Baumgartl P. Practolol (ICI 50172) zur oralen Therapie Sympatikotonen Kreislaufdysregulationen. Z Kardiol Angiol 1973;51:117–119.

    Google Scholar 

  29. Thulesius O, Hansson R, List E. Cardiospecific betaadrenergic blockade in the treatment of nervous heart symptoms. Curr Ther Res 1973;15:805–814.

    Google Scholar 

  30. Saul P, Jones BP, Edwards KG, Tweed JA. Randomized comparison of atenolol and placebo in the treatment of anxiety: A double-blind study. Eur J Clin Pharmacol 1985;28: (Suppl):109–110.

    Google Scholar 

  31. Chang PC, Van Veen S, Vermely P, Van Brummelen PE. Beta1-selectivity of bisoprolol compared with atenolol. Br J Clin Pharmacol 1987;23:625P-626P.

    Google Scholar 

  32. Leopold G, Ungethum W, Pabst J, et al. Pharmacodynamic profile of bisoprolol, a new beta1-selective adrenoceptor antagonist. Br J Clin Pharmacol 1986;22:293–300.

    Google Scholar 

  33. Prichard BN. Bisoprolol: A new beta-adrenoceptor blocking drug. Eur Heart J 1987;8(Suppl M):121–129.

    Google Scholar 

  34. Hamilton H. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;2:356–362.

    Google Scholar 

  35. Hallstrom C, Treasaden I, Edwards JC, et al. Diazepam, propranolol and their combination in the management of chronic anxiety. Br J Psychiatry 1981:139:417–421.

    Google Scholar 

  36. Tyrer PJ, Lader MH. Responses to propranolol and diazepam in somatic and psychic anxiety. Br Med J 1974;2:14–24.

    Google Scholar 

  37. Tyrer PJ, Lader MH. Physiological and psychological effects of propranolol and diazepam in anxiety. Br J Clin Pharmacol 1974;1:379–385.

    Google Scholar 

  38. Granville-Grossman KL. Propranolol, anxiety and the centeral nervous system. Br J Clin Pharmacol 1974;1:361–363.

    Google Scholar 

  39. Hayes PE, Schulz SC. The use of beta-adrenergic blocking agents in anxiety disorders and schizophrenia. Pharmacotherapy 1983;3:101–117.

    Google Scholar 

  40. Granville-Grossman L, Turner P. The effect of propranolol on anxiety. Lancet 1966;1:788–790.

    Google Scholar 

  41. Cruickshank JM, Prichard BN. Beta-blockers and the hyperkinetic heart syndrome or neurocirculatory asthenia. In: Cruickshank JM, Prichard BN, eds. Beta-blockers in clinical practice. New York: Churchill Livingstone, 1988: 658–659.

    Google Scholar 

  42. Frishman WH, Teicher W. Beta-adrenergic blockade. An update. Cardiology 1985;72:280–296.

    Google Scholar 

  43. Prichard BN, Tomlinson B. The additional properties of beta-adrenoceptor blocking drugs. J Cardiovasc Pharmacol 1986;8(Suppl 4):S1-S15.

    Google Scholar 

  44. Cruickshank JM. Clinical importance of cardioselectivity and lipophilicity of beta-blockers. Am Heart J 1980;100: 160–175.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fogari, R., Zoppi, A., Corradi, L. et al. Comparison of bisoprolol and diazepam in the treatment of cardiac neurosis. Cardiovasc Drug Ther 6, 249–253 (1992). https://doi.org/10.1007/BF00051146

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00051146

Key Words

Navigation